{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:52Z","timestamp":1787009872448,"version":"build-2736575974"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>To summarize the findings of studies investigating patients with rheumatoid arthritis (RA) and risk of acute and postacute COVID-19 outcomes 3 years into the pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Most studies early in the pandemic included all patients with systemic autoimmune rheumatic diseases (SARDs), not only those with RA, due to limited sample size. Many of these studies found that patients with SARDs were at higher risk of COVID-19 infection and severe outcomes, including hospitalization, hyperinflammation, mechanical ventilation, and death. Studies performed later were able to focus on RA and found similar associations, while also identifying RA-specific factors such as immunosuppressive medications, disease activity\/severity, and interstitial lung disease as risk factors for severe COVID-19. After COVID-19 vaccination, the risks for COVID-19 infection and severity were reduced for patients with RA, but a gap between the general population persisted, and some patients with RA are susceptible to breakthrough infection after vaccination. Preexposure prophylaxis, effective treatments, and changes in viral variants have also contributed to improved COVID-19 outcomes throughout the pandemic. Emerging data suggest that patients with RA may be at risk for postacute sequelae of COVID-19 (PASC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Although COVID-19 outcomes have improved over the pandemic for patients with RA, some experience poor acute and postacute outcomes after COVID-19. Clinicians and patients should remain vigilant about risk mitigation for infection and consider early treatment for RA patients with COVID-19. Future studies are needed to investigate clinical outcomes and mechanisms of PASC among patients with RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000930","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:02:07Z","timestamp":1675839727000},"page":"175-184","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic"],"prefix":"10.1097","volume":"35","author":[{"given":"Alessandra","family":"Zaccardelli","sequence":"first","affiliation":[{"name":"Tufts University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology"},{"name":"Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital"},{"name":"Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[{"name":"Harvard Medical School"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid arthritis","volume":"170","author":"Sparks","year":"2019","journal-title":"Ann Intern Med"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"102243","DOI":"10.1016\/j.coph.2022.102243","article-title":"Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases","volume":"65","author":"Paik","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u2018hot spot\u2019","volume":"79","author":"D'Silva","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2665-9913(21)00140-5","article-title":"Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study","volume":"3","author":"Hsu","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/annrheumdis-2020-219279","article-title":"Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic","volume":"80","author":"Serling-Boyd","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/acr.24883","article-title":"Assessing the severity of COVID-19 lung injury in rheumatic diseases versus the general population using deep learning-derived chest radiograph scores","volume":"75","author":"Patel","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2020-219808","article-title":"SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease","volume":"80","author":"D'Silva","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/acr2.11386","article-title":"Coronavirus disease 2019 outcomes among recipients of anti-CD20 monoclonal antibodies for immune-mediated diseases: a comparative cohort study","volume":"4","author":"Patel","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/acr2.11481","article-title":"Development of a prediction model for COVID-19 acute respiratory distress syndrome in patients with rheumatic diseases: results from the Global Rheumatology Alliance registry","volume":"4","author":"Izadi","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"e2129639","DOI":"10.1001\/jamanetworkopen.2021.29639","article-title":"Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19","volume":"4","author":"Izadi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/art.41567","article-title":"Association of race and ethnicity with COVID-19 outcomes in rheumatic disease: data from the COVID-19 Global Rheumatology Alliance Physician registry","volume":"73","author":"Gianfrancesco","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/S2665-9913(22)00192-8","article-title":"Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study","volume":"4","author":"Izadi","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.42030","article-title":"SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis","volume":"74","author":"Conway","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1016\/S2665-9913(21)00175-2","article-title":"Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases","volume":"3","author":"Hausmann","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2665-9913(22)00001-7","article-title":"COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey","volume":"4","author":"Putman","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"e001814","DOI":"10.1136\/rmdopen-2021-001814","article-title":"Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey","volume":"7","author":"Sattui","year":"2021","journal-title":"RMD Open"},{"issue":"(SI2)","key":"R21-20250526","doi-asserted-by":"crossref","first-page":"SI143","DOI":"10.1093\/rheumatology\/keac249","article-title":"Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey","volume":"61","author":"Rider","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/acr2.11340","article-title":"Perceived risk and associated shielding behaviors in patients with rheumatoid arthritis during the coronavirus 2019 pandemic","volume":"3","author":"Cook","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/art.41800","article-title":"Risk of COVID-19 in rheumatoid arthritis: a national veterans affairs matched cohort study in at-risk individuals","volume":"73","author":"England","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/acr.24831","article-title":"Increased risk of COVID-19 in patients with rheumatoid arthritis: a general population-based cohort study","volume":"74","author":"Wang","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R25-20250526","first-page":"1577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"384","author":"Vergnes","year":"2021","journal-title":"N Engl J Med"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1016\/S2665-9913(22)00096-0","article-title":"Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021 in Ontario, Canada: a population-based analysis","volume":"4","author":"Widdifield","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann Intern Med"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US","volume":"182","author":"Sun","year":"2022","journal-title":"JAMA Intern Med"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/annrheumdis-2021-221326","article-title":"Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases","volume":"81","author":"Cook","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"e002187","DOI":"10.1136\/rmdopen-2021-002187","article-title":"SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry","volume":"8","author":"Liew","year":"2022","journal-title":"RMD Open"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"e002082","DOI":"10.1136\/rmdopen-2021-002082","article-title":"Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy","volume":"8","author":"Vanni","year":"2022","journal-title":"RMD Open"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"152108","DOI":"10.1016\/j.semarthrit.2022.152108","article-title":"Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study","volume":"58","author":"Patel","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"R34-20250526","article-title":"Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: a general population study","author":"Li","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1093\/rheumatology\/keab223","article-title":"COVID-19 vaccination and antirheumatic therapy","volume":"60","author":"Arnold","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2665-9913(21)00394-5","article-title":"Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study","volume":"4","author":"Jyssum","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.41619","article-title":"COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study","volume":"73","author":"D'Silva","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/S2665-9913(20)30422-7","article-title":"Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study","volume":"3","author":"Jorge","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"e0258154","DOI":"10.1371\/journal.pone.0258154","article-title":"Association of preexisting comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: a population-based cohort study","volume":"16","author":"Ge","year":"2021","journal-title":"PLoS One"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3899\/jrheum.210888","article-title":"Characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with autoimmune conditions treated with systemic therapies: a population-based study","volume":"49","author":"Curtis","year":"2022","journal-title":"J Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.semarthrit.2021.08.010","article-title":"Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States","volume":"51","author":"Raiker","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1016\/S2665-9913(22)00227-2","article-title":"Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study","volume":"4","author":"Figueroa-Parra","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/rheumatology\/keac241","article-title":"COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis","volume":"62","author":"Cordtz","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/annrheumdis-2021-219845","article-title":"Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study","volume":"80","author":"Bower","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"e001987","DOI":"10.1136\/rmdopen-2021-001987","article-title":"Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision","volume":"7","author":"Bower","year":"2021","journal-title":"RMD Open"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"152149","DOI":"10.1016\/j.semarthrit.2022.152149","article-title":"Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: a retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)","volume":"58","author":"Singh","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1136\/ard-2022-222954","article-title":"Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave","volume":"81","author":"Kawano","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"e002557","DOI":"10.1136\/rmdopen-2022-002557","article-title":"Early experience with tixagevimab\/cilgavimab preexposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity","volume":"8","author":"Calabrese","year":"2022","journal-title":"RMD Open"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.42287","article-title":"Breakthrough SARS-CoV-2 infections in patients with immune-mediated disease undergoing B cell-depleting therapy: a retrospective cohort analysis","volume":"74","author":"Calabrese","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R53-20250526","article-title":"Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study","author":"Qian","year":"2022","journal-title":"medRxiv"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.11.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"16144","DOI":"10.1038\/s41598-021-95565-8","article-title":"More than 50 long-term effects of COVID-19: a systematic review and meta-analysis","volume":"11","author":"Lopez-Leon","year":"2021","journal-title":"Sci Rep"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"698169","DOI":"10.3389\/fmicb.2021.698169","article-title":"Long COVID or postacute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms","volume":"12","author":"Proal","year":"2021","journal-title":"Front Microbiol"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"A clinical case definition of post-COVID-19 condition by a Delphi consensus","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"152025","DOI":"10.1016\/j.semarthrit.2022.152025","article-title":"DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective study","volume":"55","author":"Di Iorio","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"e002587","DOI":"10.1136\/rmdopen-2022-002587","article-title":"Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey","volume":"8","author":"DiIorio","year":"2022","journal-title":"RMD Open"},{"key":"R62-20250526","article-title":"Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases","author":"Patel","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R63-20250526","article-title":"Impact of cross-coronavirus immunity in postacute sequelae of COVID-19","author":"Herman","year":"2022","journal-title":"medRxiv"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"eabj2901","DOI":"10.1126\/sciimmunol.abj2901","article-title":"Early cross-coronavirus reactive signatures of humoral immunity against COVID-19","volume":"6","author":"Kaplonek","year":"2021","journal-title":"Sci Immunol"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40674-020-00160-z","article-title":"Rheumatoid arthritis-associated interstitial lung disease: current update on prevalence, risk factors, and pharmacologic treatment","volume":"6","author":"Huang","year":"2020","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1093\/rheumatology\/keac152","article-title":"Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset","volume":"61","author":"McDermott","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N Engl J Med"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"e2200031","DOI":"10.1002\/prca.202200031","article-title":"Plasma biomarkers for systemic inflammation in COVID-19 survivors","volume":"16","author":"Zhao","year":"2022","journal-title":"Proteomics Clin Appl"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"e154886","DOI":"10.1172\/JCI154886","article-title":"The intersection of COVID-19 and autoimmunity","volume":"131","author":"Knight","year":"2021","journal-title":"J Clin Invest"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:19:29Z","timestamp":1748279969000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000930","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]}}}